Global pharmaceutical company Pfizer (NYSE: PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know.
Pfizer beat analysts’ revenue expectations by 3% last quarter, reporting revenues of $17.76 billion, up 24.7% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ organic revenue and EPS estimates.
Is Pfizer a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Pfizer’s revenue to decline 5.9% year on year to $14 billion, improving from the 19.5% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.69 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pfizer has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Pfizer’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Merck reported a revenue decline of 1.6%, topping estimates by 1.6%. Bristol-Myers Squibb traded down 1.3% following the results while Merck was up 5.1%.
Read our full analysis of Bristol-Myers Squibb’s results here and Merck’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. Pfizer is down 9.5% during the same time and is heading into earnings with an average analyst price target of $29.50 (compared to the current share price of $22.94).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
